Algert Global LLC Acquires 33,777 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Algert Global LLC raised its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 86.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 73,069 shares of the company's stock after buying an additional 33,777 shares during the period. Algert Global LLC owned about 0.06% of Vaxcyte worth $5,981,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Whipplewood Advisors LLC bought a new position in shares of Vaxcyte during the 4th quarter valued at $28,000. Smartleaf Asset Management LLC increased its holdings in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after buying an additional 260 shares during the period. National Bank of Canada FI purchased a new position in shares of Vaxcyte in the fourth quarter worth about $41,000. Blue Trust Inc. lifted its stake in shares of Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after acquiring an additional 371 shares during the last quarter. Finally, Assetmark Inc. grew its position in Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company's stock worth $64,000 after acquiring an additional 775 shares during the last quarter. 96.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Bank of America dropped their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. The Goldman Sachs Group cut their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Guggenheim reissued a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Vaxcyte currently has a consensus rating of "Buy" and a consensus target price of $136.50.

Vaxcyte Price Performance

PCVX stock traded down $0.29 during midday trading on Friday, hitting $31.16. The stock had a trading volume of 2,030,375 shares, compared to its average volume of 1,306,324. The business has a 50-day moving average of $46.66 and a two-hundred day moving average of $74.72. The firm has a market cap of $4.02 billion, a price-to-earnings ratio of -6.77 and a beta of 1.27. Vaxcyte, Inc. has a 52-week low of $27.66 and a 52-week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period in the previous year, the firm earned ($0.85) EPS. Research analysts predict that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Insider Buying and Selling at Vaxcyte

In other news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.